Presentation is loading. Please wait.

Presentation is loading. Please wait.

Wald DS, et al. Am J Med 2009;122:290-300. Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:290-300.

Published byLinda Fox Modified over 8 years ago

Similar presentations

Presentation on theme: "Wald DS, et al. Am J Med 2009;122:290-300. Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:290-300."— Presentation transcript:

1 Wald DS, et al. Am J Med 2009;122:290-300

2 Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:290-300

3 Details of the 42 Trials Included in the Meta-analysis - Part II Wald DS, et al. Am J Med 2009;122:290-300

4 Details of the 42 Trials Included in the Meta-analysis - Part III Wald DS, et al. Am J Med 2009;122:290-300

5 Details of the 42 Trials Included in the Meta-analysis - Part IV Wald DS, et al. Am J Med 2009;122:290-300

6 Mean placebo-subtracted systolic blood pressure reduction from a meta-analysis of 42 randomized factorial trials of thiazides, beta-blockers, ACE inhibitors, or calcium channel blockers Wald DS, et al. Am J Med 2009;122:290-300

7 Ratio of observed to expected incremental blood pressure-lowering effects of adding a drug or doubling the dose according to the class of drug Wald DS, et al. Am J Med 2009;122:290-300

8 Comparison of observed placebo-subtracted reduction in systolic blood pressure of 2 drugs together against the expected effect of 2 drugs together Wald DS, et al. Am J Med 2009;122:290-300

Download ppt "Wald DS, et al. Am J Med 2009;122:290-300. Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:290-300."

Similar presentations

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.
Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.
ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.

ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.
CHARM Program: 3 Component trials comparing candesartan with placebo.

CHARM Program: 3 Component trials comparing candesartan with placebo.
חזק בהגנה לבבית Valsartan in Heart Failure

חזק בהגנה לבבית Valsartan in Heart Failure
NHANES III Prevalence of Hypertension* According to BMI

NHANES III Prevalence of Hypertension* According to BMI
Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3):193-199. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.

Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3): Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.
Nursing 210 Advanced Cardiac UNIT 2 Laurie Brown RN, MSN, MPA-HA, CCRN.

Nursing 210 Advanced Cardiac UNIT 2 Laurie Brown RN, MSN, MPA-HA, CCRN.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of.

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of.
Pharmacological Treatment of Hypertension Update 2012.

Pharmacological Treatment of Hypertension Update 2012.
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.

ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.

Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Similar presentations

Ads by Google